A Phase 2 interventional study of Hydroxychloroquine and Vitamin C in COVID-19, Coronavirus Infection and Sars-CoV2, sponsored by ProgenaBiome. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by ProgenaBiome · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing hydroxychloroquine in COVID-19 — 3 open to participants now, 3 under way, 2 of them phase 3. Hydroxychloroquine · COVID-19.
Among the 125 studies testing hydroxychloroquine in COVID-19, this one is the 43rd largest by enrollment, is one of 118 that started in 2020, is one of 29 in phase 2, and was the 26th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →3 of the 125 studies testing hydroxychloroquine in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:
University of Oxford · Sites in Brazil, Laos, Nepal and 2 more countries
Ages 18–60
University of Oxford · Sites in Belgium, Estonia, France and 13 more countries
Ages 0+
UMC Utrecht · Sites in United States, Australia, Belgium and 26 more countries
Ages 28 days+
By country, each count listing its studies:
Hydroxychloroquine: first FDA approval 1955 (PLAQUENIL). What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 49 · Phase 3 67 · Phase 4 11
First in 2016; this study’s year is marked. 118 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 254 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 105 across the 125 interventional studies. Of the 70 that completed or were terminated, 26 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 125 have an industry lead sponsor. The 10 most frequent:
ProgenaBiome is the lead sponsor of 47 studies on the registry; 2 are open to participants now.
ProgenaBiome has 7 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
1 of the studies testing hydroxychloroquine in COVID-19 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05041907University of OxfordFinding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 125 studies testing hydroxychloroquine in COVID-19, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase II interventional study testing whether treatment with hydroxychloroquine, Vitamin C, Vitamin D, and Zinc can prevent symptoms of COVID-19
In this study, subjects will take a regimen of hydroxychloroquine, vitamin C, vitamin D, and Zinc to test if this combination can prevent COVID-19. Treatment with hydroxychlorquine will last 1 day. Treatment with vitamin C, vitamin D, and and zinc will last 12 weeks. The study will last 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female patients 18 years of age or older that are considered to be high-risk individuals.
a. High-risk individuals are defined as all health care workers in hospitals, clinics, and emergency rooms, and medical facilities.
Exclusion Criteria:
Any for treatment with hydroxychloroquine including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Medical workers who are exposed to COVID-19 and as such are at higher risk for infection.
Drug: Hydroxychloroquine · Dietary Supplement: Vitamin C · Dietary Supplement: Vitamin D · Dietary Supplement: Zinc
Medical workers who are exposed to COVID-19 and as such are at a higher risk for infection
Dietary Supplement: Vitamin C · Dietary Supplement: Vitamin D · Dietary Supplement: Zinc
Prophylaxis treatment for COVID-19
Also known as: Plaquenil
Prophylaxis treatment for COVID-19
Prophylaxis treatment for COVID-19
Prophylaxis treatment for COVID-19
Number of Participants Who Tested Negative and Positive for COVID-19
Any symptoms of COVID-19 will be recorded in a daily diary. Symptoms (including fever measured in degrees Fahrenheit, dry cough, productive cough, difficulty speaking, wheezing, dry mouth, headache, chest tightness, difficulty with exertion, shortness of breath, sore throat, malaise, and diarrhea) will be rated as not present, mild, moderate, or severe.
Time frame: 24 weeks
Adverse Events
To assess the presence or absence of side effects (graded 1-5)
Time frame: 24 weeks
Patients were recruited from the PI's medical clinic, word-of-mouth, and www.clinicaltrials.gov.
| Milestone | Medical Workers | Placebo |
|---|---|---|
| Started | 90 | 82 |
| Completed | 68 | 64 |
| Not completed | 22 | 18 |
| Withdrew: Withdrawal by subject | 15 | 6 |
| Withdrew: Lack of efficacy | 7 | 12 |
Any symptoms of COVID-19 will be recorded in a daily diary. Symptoms (including fever measured in degrees Fahrenheit, dry cough, productive cough, difficulty speaking, wheezing, dry mouth, headache, chest tightness, difficulty with exertion, shortness of breath, sore throat, malaise, and diarrhea) will be rated as not present, mild, moderate, or severe.
| Participants | Medical Workers | Placebo |
|---|---|---|
| COVID Negative | 83 | 70 |
| COVID Positive | 7 | 12 |
To assess the presence or absence of side effects (graded 1-5)
| participants | Medical Workers | Placebo |
|---|---|---|
| AE Experienced | 36 | 37 |
| No AE | 54 | 45 |
Collected over One year 11 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/82 (0%) | 12/82 (14.6%) | 28/82 (34.1%) |
| Medical Workers | 0/90 (0%) | 7/90 (7.8%) | 25/90 (27.8%) |
| Event | Placebo | Medical Workers |
|---|---|---|
| COVID +General disorders | 12/82 | 7/90 |
| Event | Placebo | Medical Workers |
|---|---|---|
| HeadacheNervous system disorders | 21/82 | 13/90 |
| FatigueGeneral disorders | 13/82 | 9/90 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/82 | 6/90 |
| DiarrheaGastrointestinal disorders | 7/82 | 7/90 |
| Age, Continuous(years) | Placebo | Medical Workers | Total |
|---|---|---|---|
| Mean | 48.23 (18 to 86) | 47.56 (21 to 70) | 47.89 (18 to 86) |
| Sex: Female, Male(Participants) | Placebo | Medical Workers | Total |
|---|---|---|---|
| Female | 64 | 61 | 125 |
| Male | 18 | 29 | 47 |
| Race (NIH/OMB)(Participants) | Placebo | Medical Workers | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 5 | 7 |
| White | 72 | 72 | 144 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 6 | 11 | 17 |
| Previous COVID-19 Infection(Participants) | Placebo | Medical Workers | Total |
|---|---|---|---|
| COVID Positive | 12 | 7 | 19 |
| COVID Negative | 70 | 83 | 153 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2020 to primary completion in May 2022, 23 months.
Results were first posted in Nov 2026, 4 years 5 months after primary completion.
Of 359 non-industry phase 2 interventional studies under COVID-19, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 23 months is above that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hydroxychloroquine
ProgenaBiome